NCT02432963 2026-01-28Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior TherapyCity of Hope Medical CenterPhase 1 Active not recruiting11 enrolled
NCT05859074 2025-12-03A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor CancerMemorial Sloan Kettering Cancer CenterPhase 1 Recruiting56 enrolled
NCT04370587 2025-10-08A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid TumorsImmVira Pharma Co. LtdPhase 1/2 Recruiting30 enrolled
NCT06413095 2024-05-14PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STSPresage BiosciencesPhase EARLY_PHASE1 Completed13 enrolled
NCT04541108 2024-04-18Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer TherapiesPresage BiosciencesPhase EARLY_PHASE1 Recruiting15 enrolled
NCT03454451 2023-12-21CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersCorvus Pharmaceuticals, Inc.Phase 1 Completed117 enrolled
NCT04099277 2021-08-31A Study of LY3435151 in Participants With Solid TumorsEli Lilly and CompanyPhase 1 Terminated2 enrolled 8 charts
NCT02452424 2020-03-05A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid TumorsDaiichi SankyoPhase 1/2 Terminated78 enrolled 19 charts